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Controlled Release Systems for
Non-Viral Vectors
Lonnie D. Shea and Angela K. Pannier
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A

dapting controlled release technologies to
the delivery of non-viral vectors has the
potential to overcome barriers that limit gene
therapy. Controlled release systems can enhance
gene delivery and increase the extent and duration of transgene expression relative to more
traditional delivery methods. Delivery vehicles
for controlled release are fabricated from natural
and synthetic polymers, which function either
by releasing the vector into the local tissue environment or by maintaining the vector at the
polymer surface. Vector release or binding is
regulated by the effective affinity of the vector
for the polymer, which depends upon the
strength of molecular interactions. These interactions occur through non-specific binding
based on vector and polymer composition or
through the incorporation of complementary
binding sites (e.g., biotin-avidin). This review
examines the delivery of non-viral vectors from
natural and synthetic polymers, and presents
opportunities for continuing developments
to increase their applicability.
Introduction

Controlled release systems for low molecular
weight drugs and proteins have become a multibillion dollar industry, with products such as
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Nutropin® Depot, Gliadel® wafer, Norplant,
and CYPHER™ Stent. These systems illustrate
the potential advantages of controlled release,
which include: (1) maintained drug levels
within a desirable range, (2) localized delivery
to a target tissue or cell type to avoid adverse
side effects, (3) decreased dose or number of
dosages, and (4) facilitated delivery for fragile
compounds (i.e., short half-lives). The adaptation of controlled release technologies to the
delivery of non-viral vectors has the potential
to overcome barriers that limit gene therapy.
Controlled release can maintain elevated DNA
concentrations in the cellular microenvironment,
which improves gene delivery1. Additionally,
non-viral vectors may have a relatively short
half-life2, and delivery vehicles can either prevent
their degradation or provide a sustained release.
This review examines gene delivery from
biomaterials and discusses how continuing
advances will increase their applicability.
Delivery mechanisms

Controlled release systems typically employ
polymeric biomaterials that deliver vectors
according to two general mechanisms: i) polymeric release in which the DNA is released from
the polymer or ii) substrate-mediated in which
DNA is retained at the surface. For polymeric
release, DNA is entrapped within the material
and released into the environment, with release
typically occurring through a combination of
diffusion and polymer degradation. Polymeric
delivery may enhance gene transfer by first
protecting DNA from degradation, and then
maintaining the vector at effective concentrations, extending the opportunity for
internalization. DNA release into the tissue can
occur rapidly, as in bolus delivery, or extend
over days to months3-5. Conversely, substratemediated delivery, also termed solid phase
delivery, describes the immobilization of DNA
to a biomaterial or extracellular matrix, which
functions to support cell adhesion and places
DNA directly in the cellular microenvironment.
Cells cultured on the substrate can internalize
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the DNA either directly from the surface, or by
degrading the linkage between the vector and
the material6.
Vehicle formulations

Vehicles for gene delivery can be fabricated
from both natural and synthetic polymers and
processed into a variety of forms, including
nanospheres, microspheres, or scaffolds.
Nanospheres are particles with diameters ranging from approximately 50 nm to 700 nm7,
consistent with the size of non-viral vectors.
Nanoparticles are internalized and release DNA
intracellularly. In contrast, microspheres with
diameters ranging from 2 µm to 100 µm, are
not readily internalized, but retained within
the tissue to release DNA8,9. Released DNA
can transfect cells at the delivery site, with the
protein product acting locally or distributed
systemically9,10. Alternatively, polymeric scaffolds
function to define a three-dimensional space and
can either be implanted or designed to solidify
upon injection. These scaffolds can deliver DNA
to cells within the surrounding tissue, or can
target those infiltrating the scaffold5,10.
A variety of natural and synthetic materials have
been employed for DNA delivery, which can
be categorized as either hydrophobic (e.g.,
poly(lactide-co-glycolide) (PLG), polyanhydrides) or hydrophilic polymers (e.g., hyaluronic
acid (HA), collagen, poly(ethylene glycol)
(PEG)). Synthetic polymers such as PLG and
polyanhydrides have been widely used in drug
delivery applications, as they are biocompatible
and available in a range of copolymer ratios to
control their degradation. Drug release from
these polymers typically occurs through a
combination of surface desorption, drug diffusion, and polymer degradation11. Alternatively,
hydrogels, which are often more than 98%
water and maintain the activity of encapsulated
vectors, released DNA by diffusion from the
polymer network4, which can be controlled
by crosslinking the polymer12.

The Journal of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Vol. IX

85898 NUMS Journal

5/14/04

2:27 PM

Page 37

Naked DNA
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Naked DNA delivery by traditional mechanisms
generally results in low but sustained expression
in vivo, which is limited by poor uptake due
to factors such as degradation and clearance.
Physical (e.g., ultrasound, hydrodynamic injection) and chemical (e.g., cationic lipids/
polymers) methods are continually being
improved to enhance cellular uptake of naked
DNA by altering cell permeability or enhancing
cellular interactions13. Nevertheless, polymeric
delivery represents an alternative approach that
can increase residence time within the tissue
and protect against degradation.
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Figure 1. Range of release rates of DNA from PLG scaffolds
achieved through variations in the fabrication process.
Reprinted from the Journal of Controlled Release, Vol. 93 (1), Jang and Shea,
“Controlled Release Systems for….”, 2 Figures only, pp. 69-84. Copyright
(2003), with permission from Elsevier.

Naked DNA interacts weakly with many polymers, leading to release from the vehicle with
rates modulated by the polymer properties.
Collagen based materials released naked DNA
in vitro for times ranging from hours to days4,14,
yet intramuscular implantation of collagen
pellets maintained the DNA locally for 60
days15. HA-based hydrogels also release the
DNA; however, the rate of release can be
controlled by the extent of crosslinking12,16. For
synthetic polymers such as PLG, the integrity of
the DNA can be affected by degradation of the
polymer to lactic acid and glycolic acid5. PLG
polymers can provide release rates ranging from
a few days to more than 60 days (Figure 1),
with the fabrication method and the polymer
composition regulating release15,17,18. Ethylene
vinyl-co-acetate (EVAc) polymers can similarly
provide a sustained release of DNA on the time
scale of weeks19.
DNA releasing polymers administered to multiple sites in vivo have demonstrated the capacity
to transfect cells locally and promote sustained
protein production. An injectable PLG formulation delivered subcutaneously led to 28 days of
expression with 50 µg of DNA17. An implantable
PLG scaffold delivering 500 µg of DNA was
able to transfect cells within and adjacent to the
scaffold, and promote physiological responses5.
Collagen minipellets containing 50 µg of DNA

administered intramuscularly elicited systemic
effects for at least 60 days, which was significantly longer than direct DNA injection9.
DNA Complexes

Although naked DNA provides transfection
in vivo, packaging DNA with cationic lipids
or polymers can enhance in vivo transfection.
Complexes of naked DNA with cationic polymers or lipids facilitate cellular internalization,
by creating a less negative surface charge and
providing stability against degradation20. The
presence of complexation agents can also maintain the stability of DNA complexes during
polymer processing21, and in some cases increase
encapsulation efficiency22. Porous PLG or collagen scaffolds with encapsulated polyplexes or
lipoplexes achieved substantial transfection
in vitro4,23 and in vivo4, but with significantly
altered release profiles compared to naked
DNA, due to interactions of the complexation
reagents with the biomaterial or with adsorbed
serum components24.
Interactions between complexation agents and
the polymer have been adapted to specifically
immobilize DNA complexes to a substrate.
Poly(L-lysine) (PLL) and PEI were modified
with biotin residues for subsequent complexation with DNA and binding to a neutravidin
substrate6,25. Complexes were formed with
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mixtures of biotinylated and non-biotinylated
cationic polymer at a constant N/P ratio. For
complexes formed with PLL, the number of
biotin groups and their distribution among
the cationic polymer were critical determinants
of both binding and transfection (Figure 2).
Increasing the number of biotin groups per
complex led to increased binding6. However,
transfection was maximal when complexes
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Figure 2. Density and transfection of substrate associated
DNA/polylysine complexes formed with varying biotin distribution. (A) DNA density and (B) transgene expression for
complexes formed at a charge ratio of 5.5:1. The notation
K214-B indicates that polylysine (K) has 214 monomers on average and is biotinylated (B), with the number of biotin residues
per polylysine following. The numbers in parentheses below each
bar represent the average moles of biotin per mole of DNA. The
data is presented as the average ± the standard deviation and
the symbol * indicates statistical significance at a level of p
<0.05 for the comparisons indicated. p values were obtained
using the student t test with the single comparisons. The label
NA and TCP indicates the substrate was neutravidin and tissue
culture polystyrene respectively.
Reprinted from the Journal of Controlled Release, Vol. 93 (1), Jang and Shea,
“Controlled Release Systems for….”, 2 Figures only, pp. 69-84. Copyright
(2003), with permission from Elsevier.

contained biotin residues attached to a small
fraction of the cationic polymers25. At this
condition, less than 100 ng of immobilized
DNA mediated transfection, which was
increased 100 fold relative to bolus delivery
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of similar complexes6. For complexes formed
with PEI, substantial transfection was observed,
but was independent of the number of biotin
groups present on the complex, which suggests
that complex binding occurred by non-specific
interactions with the substrate25. Other systems
have used non-specific binding to mediate
delivery. PLGA and collagen membranes were
coated with phosphatidyl glycerol (1-5%) to
support binding of complexes formed with
polyamidoamine (PAMAM) dendrimers26.
In vivo studies demonstrated a six to eight-fold
enhancement in transfection relative to naked
DNA delivery.

Gene Therapy: Numerous clinical trials have been
completed or are pending for a multitude of
pathologies including malignancy (e.g., colorectal, bladder, and brain). Most trials have
not shown significant therapeutic efficacy or
clinically useful responses, likely due in part to
inefficient gene transfer27,28. Polymeric-based
gene delivery systems may enhance delivery of
the vector and extend the duration of transgene
expression to achieve sufficient protein quantities
that act locally or systemically. For example, IL-2,
IL-12, and TNF-α expression induced by a DNA
releasing gelatin sponge inhibited tumor growth
in heterotopic nodules of tumor bearing mice29.
Functional Genomics: Transfected cell arrays
represent a high throughput approach to
correlate gene expression with functional
cell responses, based on gene delivery from
a surface30. In principle, this system can be
employed for numerous studies, such as screening large collections of cDNAs30 or targets for
therapeutic intervention. Transfected cell arrays
were formed using a substrate-mediated
approach in which plasmids or adenoviruses
were mixed with collagen and spotted onto
glass slides or into wells30,31. Plated cells were
transfected and could be analyzed for cellular
responses using a variety of imaging or
biochemical techniques.
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Conclusions

In comparison to traditional gene delivery
systems, controlled release can enhance gene
delivery by increasing the extent and duration
of transgene expression, while reducing the
need for multiple interventions. These polymerbased gene delivery systems capitalize on both
specific and non-specific interactions between
the biomaterial and vector, to achieve either
release into the extracellular space or immobilization at the surface. While the potential to
use these polymeric systems has been established, the design parameters by which to
optimize or control gene transfer are not well
understood. Vector and biomaterial development, combined with studies that correlate
system properties (e.g., dose, release rate) with
the extent of transgene expression (i.e., quantity
and duration of protein produced, location of
transgene expression) will lead to molecular
scale design of delivery systems. The development of these systems may increase the efficacy
within current gene therapy trials, and may
also extend the applicability of gene delivery
to other areas such as functional genomics.
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